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ApolipoproteinD (ApoD) is a human glycoprotein from the lipocalin family. ApoD contains a conserved
central motif of an 8-stranded antiparallel b-sheet, which forms a beta-barrel that can be used for
transport and storage of diverse hydrophobic ligands. Due to hydrophobic nature of ApoD, it has been
difﬁcult to generate a recombinant version of this protein. In the present work, we aimed at the pro-
duction of ApoD in the robust Pichia pastoris expression system. To this end, the ApoD gene sequence was
synthesized and subcloned for expression in the yeast host cells. Following integration of the ApoD gene
into the yeast genomic region using homologous recombination, the ApoD recombinant protein was
induced using methanol, reaching its maximum induction at 96 h. Having puriﬁed the ApoD recombi-
nant protein by afﬁnity chromatography, we measured the dissociation constant (KD) using its natural
ligands: progesterone and arachidonic acid. Our results provide a viable solution to the production of
recombinant ApoD protein in lieu of previous obstacles in generating soluble and functional ApoD
protein.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
ApolipoproteinD (ApoD), a secreted glycoprotein, is amember of
lipocalin family. Proteins belonging to this family possess a
conserved fold consisting of an 8-strand antiparallel b-sheet
forming b-barrel [1,2]. Lipocalins are known as a reservoir and
transporter of diverse hydrophobic ligands [3]. Ligand binding ex-
periments of ApoD have revealed that the protein binds to impor-
tant physiological hydrophobic ligands such as arachidonic acid
and progesterone [4e6]. Several studies have suggested that ApoD
is a multifunctional and multi-ligand protein; nevertheless, its
precise function and all of its endogenous ligands are not known
[7]. Despite other lipoproteins that mainly are expressed in the
liver, main source of ApoD is in the brain [8]. Upregulation of ApoD
expression is observed in several pathological conditions such as
Alzheimer's disease [9]. In addition, ApoD is the major component
in breast gross cystic disease [10,11].
In order to investigate novel applications of ApoD protein, we
decided to efﬁciently produce a recombinant form of ApoD protein.To this end, the Pichia pastoris expression system was chosen to
express the recombinant protein. The advantages of using the
Pichia system include facile genetic engineering, high-level
expression in spite of low cost, rapid growth, easy handling and
scale up, posttranslational modiﬁcation, lack of endotoxin and viral
contamination of products, proper folding, disulﬁde bond forma-
tion, and intra/extracellular protein production [12e14]. Since the
yeast expression system could be manipulated to secrete recom-
binant proteins into extracellular media, this attribute provides the
simpliﬁcation of downstream procedures including efﬁcient puri-
ﬁcation of recombinant proteins. Furthermore, due to extracellular
expression in the yeast system, the puriﬁcation steps would be
much simpler than in bacterial expression systems [15]. For a high-
level expression of the desired gene, a strong AOX promoter is used
in P. pastoris.
There have been a number of reports in generating the recom-
binant ApoD protein in the bacterial system. However, due to the
difﬁculty in obtaining the soluble form of ApoD, the authors had to
use site-directedmutagenesis in order to generate a soluble form of
ApoD [4,6].
In the present study, the soluble ApoD protein was produced
under the control of AOX promoter. The secreted recombinant
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and its functionality was assessed using natural interacting ligands
such as progesterone and arachidonic acid. As a ﬁnal result and
with respect to the previous reports on the recombinant expression
of ApoD in the bacterial expression system, we suggest that the P.
pastoris system is a satisfactory candidate for the ApoD production.
2. Materials and methods
2.1. Reagent and media
ApoD gene sequence was synthesized by Bioneer Corporation
(Bioneer, Korea). AOX1 primers were synthesized by Biobasic
Company (Biobasic, Canada). Ni-NTA afﬁnity chromatography col-
umn was purchased from Biobasic Corporation (Biobasic, Canada).
Minipreparation plasmid and gel extraction kits were from Geneall
(Geneall, Korea). Other reagents were purchased from Sigma.
2.2. P. pastoris media
The growth of P. pastoris was carried out in YPD (1% yeast
extract, 2% peptone, 1% dextrose) and BMGY (1% yeast extract, 2%
peptone, 0.1 M potassium phosphate buffer, pH 6.0, 1.34% Yeast
Nitrogen Base, 4  105% biotin, 1% glycerol) culture media. Protein
expressionwas performed in BMMYmedia containing methanol as
an inducer for recombinant protein production.
2.3. Construction of ApoD e pPICZaA expression vector
In order to obtain a maximum expression in the yeast system,
after removal of the native signal peptide (1e20 amino acids), the
codon sequence of mature human apolipoprotein D gene (reference
sequence: NM_001647.3) was optimized by changing synonymous
codons to those preferred by the P. pastoris host. The codon usage
program (Bioneer Corporation, South Korea) is designed to calcu-
late repeat sequences and invert sequences that cause low-quality
codon optimization process. The ﬁnal amino acid sequences of the
synthetic gene were identical to the mature native ApoD. The
introduced restriction sites were SalI and EcoRI sites. The optimized
ApoD sequence (shown in Supplementary data, S1A) was synthe-
sized in pGEM cloning vector by Bioneer Corporation. Afterwards,
the synthesized pGEM-ApoD vector was transformed into chemi-
cally competent DH5aA bacterial cells. The ApoD gene was isolated
with enzyme digestion and subsequently was ligated into the
pPICZaA expression vector with N-terminal a-factor secretion
signal and 6-histidine tag in C-terminus with T4 ligase enzyme. The
transformed colonies with the recombinant ApoD-pPICZaA vector
were selected on Low Salt LB plate with 25 mg/ml zeocin concen-
tration. Ultimately, DNA sequencing and restriction enzyme di-
gestions were used to conﬁrm correct insertion.
2.4. Transformation and selection of positive recombinant P.
pastoris yeast cells
The recombinant ApoD-pPICZaA vector was linearized using
SacI enzyme. Subsequently, the digested vector was transformed
into the P. pastoris genome by electroporation method at 1500 V.
Recombinant P. pastoris was selected on YPDS plate (YPD medium
with 1 M sorbitol) with 100 mg/ml zeocin concentration, and the
cells were incubated for 3 days, at 30 C. The successful integration
of recombinant plasmid was conﬁrmed using PCR reactions; the
template for the PCR reactions was extracted using LiOAc protocol.
Eventually, DNA sequencing was performed on the ampliﬁed
products.2.5. Expression of recombinant ApoD
For the expression of recombinant ApoD, recombinant Pichia
cells were cultivated in BMGY mass media for 18 h up to the optical
density of equal 2. The biomass was separated with centrifugation
and subsequently the cells were inoculated in BMMY expression
media for 96 h; 1% methanol was added to the media every 24 h.
2.6. SDS-PAGE and mass spectrometry analysis
In order to detect the protein expression, yeast cells were
removed from BMMYmedia by centrifugation after 96 h induction.
Supernatant was analyzed with 12% SDS-PAGE. To further conﬁrm
ApoD expression, the corresponding band on SDS-PAGE was cut
and analyzed with LC/MS-MS method as the following protocol.
The protein band was excised from the gel and chopped into small
pieces. In-gel digestion was performed with 500 ng trypsin in
50 mM ammonium bicarbonate overnight at 37 C. The digested
peptides were separated by nano-liquid chromatography using
DionexUltiMate 3000 RSLC equipped with an analytical column.
Then the peptides were injected into a high capacity trap (HCT)
Ultra Ion Trap mass spectrometer (Bruker Daltonics) by electro-
spray ionization (ESI) at 200 C drying temperature. Finally, MS/MS
spectra were searched against the human UniProt database.
2.7. Puriﬁcation of recombinant ApoD
A nickel afﬁnity chromatography method was used for isolation
of recombinant proteinwith N-terminal 6-histidine tag. Brieﬂy, the
supernatant of expression media was dialyzed in PBS buffer, pH 8.
Ni-NTA agarose column was equilibrated with 300 mM NaCl,
50 mM NaH2PO4 buffer pH 8. After loading the dialyzed sample
onto the column, the elution steps were performed using 20, 50,
100 mM imidazole concentrations. The recombinant protein was
eluted using 100 mM imidazole concentration. The quality of pu-
riﬁcation was assessed with SDS-PAGE on different fractions. The
yield of puriﬁed ApoD recombinant was measured by Hartree
modiﬁed Lowery method using BSA as a protein standard [16].
2.8. Functional assay of ApoD
The intrinsic ﬂuorescent of recombinant ApoD was performed
using H4 Synergy Hybrid microplate reader instrument. Brieﬂy,
ﬁxed concentration of puriﬁed ApoD, 1 mM was mixed with
0e100 mM ligands (progesterone and arachidonic acid) concen-
trations. The working solution of progesterone was prepared in 10%
dioxane. The stock solution of arachidonic acid was dissolved in
100% ethanol (HPLC grade), and diluted in 10% ethanol for the
desired concentrations. The excitation and emission wavelengths
were 280 and 340 nm, respectively. After subtraction of back-
ground emission, and scaling data to the initial ﬂuorescence
(without ligand) as 100% ﬂuorescence intensity, the dissociation
constant (KD) was calculated using OriginPro Software (OriginLab
Corporation, USA) with nonlinear least square regression as pre-
viously reported [5]., The following equation was used for protein-
ligand complex:
F ¼ ½P0  ½L0  Kd f02 þ ½P0  ½L0  Kd fPL2 þ ðf0
 fPLÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ½P0  ½L0  Kd2
4
 ½P0½L0
s
½P0 and ½L0 indicate the total concentration of protein and ligand at
each titration step, respectively. f0 was the relative ﬂuorescence
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relative ﬂuorescence quenching of protein eligand complex.3. Results
3.1. Cloning of synthetic ApoD gene
Since ApoD is a human gene, we decided to express ApoD in a
robust eukaryotic expression system. For an enhanced expression
of the human gene in the P. pastoris system, an optimized sequence
of ApoD, lacking its native signal peptide, was synthesized (shown
in the Supplementary data, S1A). In order to secrete ApoD into the
media, the a-factor signal peptide from the yeast was fused in the
N-terminus of ApoD protein as shown in Fig. 1, panel A. The alpha
factor signal is designed to be processed prior to it secretes into the
media. In order to purify the recombinant ApoD protein using
nickel afﬁnity chromatography, 6-histidine residues were designed
to be included at the C-terminus. Therefore, the ﬁnal recombinant
product would only contain 6-histidine at the C-terminus (Fig. 1,
panel A). Using restriction enzyme, EcoRI and SalI, the synthetic
ApoD gene was successfully cloned into the appropriate expression
vector; positive transformants containing cloned ApoD were
selected and examined using appropriate restriction enzymes as
explained in details in Materials and Methods.Fig. 2. SDS-PAGE analysis of puriﬁed ApoD on 12% polyacrylamide gel stained with
coomassie brilliant blue R-250. Lane 1: Supernatant of media culture induced with 1%
methanol; lane2: puriﬁed ApoD. 29 kDa band is corresponding to recombinant ApoD.
The arrow indicates puriﬁed recombinant ApoD. From top to button protein marker
bands were 78.6, 50.6, 35.9, 27.1, and 19.2 respectively.3.2. Integration of recombinant ApoD into the P. pastoris genome
After veriﬁcation of the cloned gene by restriction analysis and
DNA sequencing, cloned ApoD was integrated into the P. pastoris
genome using homologous recombination with electroporation
method. The PCR analysis was exploited to conﬁrm homologous
recombination, at the appropriate sites, in the P. pastoris genome.
As shown in Fig. 1 (panel B, lane 3), 2.2 kb and approximately
1000 bp ampliﬁed products corresponding to native AOX and ApoD
fragments, respectively, conﬁrmed the integration of the ApoD
gene into the yeast genome.Fig. 1. Outline of cloning and expression of ApoD and PCR ampliﬁcation to conﬁrm homologo
Pichia pastoris. Panel B: PCR analysis on recombinant Pichia pastoris by AOX1 primers. la
recombinant vector integrated into the Pichia pastoris genome, respectively. 2.2 kb and appro
the yeast genome.3.3. Production of soluble recombinant ApoD in media
To produce ApoD recombinant protein, initially recombinant
yeast cells were grown up to OD ¼ 2 and methanol was used to
induce the ApoD expression as explained inMaterials andMethods.
Subsequently, the media were harvested after 96 h and the protein
expression was analyzed by SDS-PAGE. As shown in Fig. 2, results
indicated that the highest expression of secreted recombinant ApoD
(29 kDa) was obtained in 1%methanol after 96 h induction. In order
to conﬁrmApoDexpression, the29-kDbandwas cutoff thegel; after
performing trypsin digestion, LC/MS-MS analysis of the trypsinized
fragments conﬁrmed the presence of the ApoD protein (Fig. 3).
3.4. The puriﬁed ApoD possess ligand binding activity
As explained in Materials and Methods, the media containingus recombination. Panel A: the schematic outline for cloning and expression of ApoD in
ne 1: molecular weight marker. Lanes 2 and 3, PCR product of the empty vector and
ximately 1000 bp bands in lane 3 are correspond to native AOX and integrated ApoD in
Fig. 3. LC/MS-MS analysis of ApoD expression. The results revealed that ApoD was produced into the media culture successfully. Fragment y [9] with the larger score conﬁrmed the
sequence indicated.
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The high degree of purity of the recombinant ApoD protein was
conﬁrmed using silver staining method (S3). In order to assess the
function of the recombinant protein, the interaction of the puriﬁed
recombinant ApoD and its physiological ligands including proges-
terone and arachidonic acid were investigated. As shown in Fig. 4,
different concentrations of ligands were able to quench the
intrinsic ﬂuorescence of ApoD. KD (dissociation constant) values for
arachidonic acid and progesterone were 5.8 mM (±1.7) and 3.8
(±1.3) mM, respectively (Fig. 4).4. Discussion
ApoD is a member of lipocalin family which is abundantly
expressed in the number of tissues and plasma. It has been shown
that ApoD, due to its structural properties, binds to hydrophobic
ligands such as progesterone and arachidonic acid [17]. The precise
ApoD function has still remained unknown, but upregulation of
ApoD has been reported in the neurodegenerative conditions suchFig. 4. Determination of the dissociation constant for puriﬁed recombinant ApoD. As explai
protein (vertical axis) is plotted against total ligand concentration (horizontal axis). Panel A
Panel B: relative quenching of ApoD with progesterone (0e80 mM). The concentration of Aas Alzheimer and Parkinson, and also in prostate cancer [9,18e23].
It has been suggested that in Alzheimer's disease, when the in-
ﬂammatory response is initiated, leading to arachidonic acid de-
rivatives production, the ApoD protein could act as a scavenger to
bind the arachidonic acid derivatives leading to ApoD aggregation
[24].
Some of the applications of engineered lipocalins known as
anticalin have been used in drug delivery and recognition of non-
natural ligands [25]. For example, ApoD has been engineered to
bind hemoglobin as a ligand [26]. To investigate the recombinant
ApoD function in neurodegenerative diseases, we have decided to
produce soluble recombinant ApoD. Due to the hydrophobic nature
of ApoD, it has been challenging to produce a soluble recombinant
version of the ApoD protein [4].
In this work, we have cloned an optimized synthetic ApoD gene
in the yeast expression vector. After the integration of ApoD gene
into the Pichia genome, the secreted recombinant protein was
isolated from the gel and its trypsinized fragments were identiﬁed
using MS/MS analysis. Furthermore, using afﬁnity chromatography,ned in Materials and Methods, the relative ﬂuorescence intensity of ApoD recombinant
: Relative quenching of intrinsic ApoD ﬂuorescence with arachidonic acid (0e100 mM).
poD was 1 mM in each experiment.
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in Fig. 2. Using Lowery assay, the concentration of recombinant
ApoD was measured up to 6 mg/L in the ﬁnal pure sample from
40 mg/L of total proteins that were secreted into the culture media
(shown in Supplementary data, S2). This yield, in comparison to the
reported bacterial system, is signiﬁcantly improved.
Fluorescence titration is one of the most common functional
assays for lipocalin family members [8]. In order to measure the
activity of recombinant ApoD protein, ﬂuorescence titration assay
was performed with progesterone and arachidonic acid as its nat-
ural ligands. Based on this method, the emission of intrinsic ﬂuo-
rescence of ApoD is quenched after binding of hydrophobic ligands
[5].
As shown in Fig. 4, the interaction of arachidonic acid and
progesterone with the recombinant ApoD protein led to quenching
of intrinsic ﬂuorescence. Indeed, KD values for arachidonic and
progesterone was 5.8 and 3.8 mM, respectively. These values are
comparable to the previously reported values of bacterially pro-
duced ApoD, 3.2 mM for arachidonic acid and 3.7 mM for proges-
terone, [5]. It is plausible that posttranslational modiﬁcations that
could take place in the P. pastoris expression system may cause
some slight conformational changes of the protein during ligand
binding, leading to the differences in KD value [27]. The mechanism
of quenching the intrinsic ﬂuorescence of ApoD by the unsaturated
fatty acids is not fully understood. However, it has been suggested
that when the hydrophobic ligands interact with the ApoD protein,
a Trp residue located on a mobile loop 3 becomes more exposed to
solvent, leading to the quenching of the ﬂuorescence [4,5].
Nasreenet et al. reported the expression of soluble ApoD in the
bacterial system. However, the soluble form was created by intro-
ducing a number of mutations in the protein. Owing to the
eukaryotic origin of ApoD and with respect to the solubility prob-
lem in the bacterial system, we decided to express ApoD, without
introducing mutation, in the yeast expression system. P. pastoris is a
superior eukaryotic expression system compared with the bacterial
system due to the simple protein production procedure. In addition
the P. pastoris expression system is able to secrete a soluble form of
recombinant protein; therefore, puriﬁcation can be a facile one-
step process in native condition by afﬁnity chromatography [15].
One of the outcomes in the expression of a recombinant protein
in P. pastoris is different glycosylation as compared to higher
eukaryotic expression system. However, in P. pastoris, the recom-
binant proteins are founded to be glycosylated on the average 8e14
mannose residues per side chain of mainly Asn residues [28]. It is
assumed that because of the small number of sugar residues that
can be conjugated on the expressed protein in the yeast, glycosyl-
ation would not interfere with the function of the recombinant
protein [29]. Although we have not shown any evidence of ApoD
glycosylation in our system, it is still plausible that ApoD might
undergo glycosylation in the yeast expression system.
The expression of functional and soluble recombinant ApoD
would allow investigators to better study ApoD complex function
including its role in protein amyloid formation in Alzheimer's and
other neurodegenerative diseases.Acknowledgment
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